Celgene ( Celgene )

Celgene

Celgene's picture

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

Celgene press release, blog etc

12/11/2017 - 04:49 Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
12/07/2017 - 08:37 Long-Term Efficacy Data from the Phase III GeparSepto Study in High Risk Early Breast Cancer Patients Treated with ABRAXANE Vs. Solvent-Based Paclitaxel to Be Reported
12/05/2017 - 04:40 Celgene Launches Celgene Cancer Care Links TM to Support Cancer Healthcare Capacity Building in Resource-Constrained Countries
11/16/2017 - 07:30 Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma
11/01/2017 - 05:20 Celgene Prices $3 Billion of Senior Unsecured Notes
10/31/2017 - 07:43 Celgene Announces Offering of Senior Unsecured Notes
10/28/2017 - 08:34 Efficacy and Safety Results from Second Phase III Trial (RADIANCE Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
10/27/2017 - 09:09 Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
10/25/2017 - 17:29 Why I Advocate for People with Myelodysplastic Syndromes
10/19/2017 - 14:03 Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
10/19/2017 - 05:27 Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
10/16/2017 - 03:12 Results from Phase 2 Studies of Oral Ozanimod in Crohn's Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017
09/18/2017 - 07:50 Europe Continues to See Progress in Reducing the Burden of Multiple Myeloma
09/12/2017 - 21:40 Advancing the Hematology Field
09/07/2017 - 05:59 Celgene Provides Update on the Fusion Clinical Program
09/01/2017 - 01:14 Tracing Blood Cancer Family Tree
08/03/2017 - 20:27 Getting Patients Access to Precision Medicine Is Crucial
08/01/2017 - 11:42 FDA Grants Approval of IDHIFA, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation